Carmell Therapeutics, a biotechnology company, went public via a SPAC merger with Alpha Healthcare Acquisition, a special purpose acquisition company, in a $328m deal. “The business combination of Alpha and Carmell, allows us to advance the clinical development of our platform technology, to add significant regenerative medicine experience to the Carmell™ board of directors and to access high-quality institutional investors,” Randy Hubbell, Carmell Therapeutics President & CEO.